ES2121213T3 - Benciloxiquinuclidinas como antagonistas de la sustancia p. - Google Patents

Benciloxiquinuclidinas como antagonistas de la sustancia p.

Info

Publication number
ES2121213T3
ES2121213T3 ES94919851T ES94919851T ES2121213T3 ES 2121213 T3 ES2121213 T3 ES 2121213T3 ES 94919851 T ES94919851 T ES 94919851T ES 94919851 T ES94919851 T ES 94919851T ES 2121213 T3 ES2121213 T3 ES 2121213T3
Authority
ES
Spain
Prior art keywords
pct
c6alkyl
c6alkoxy
sec
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94919851T
Other languages
English (en)
Inventor
Kunio Satake
Hiroaki Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2121213T3 publication Critical patent/ES2121213T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

UN COMPUESTO DE LA FORMULA QUIMICA (I) Y SU SAL FARMACEUTICAMENTE ACEPTABLE, EN LA QUE X E Y SON CADA UNO HIDROGENO, HALOGENO, ALQUILO C{SUB,1}-C{SUB,6}, ALQUILO C{SUB,1}C{SUB,6} HALOSUSTITUIDO, ALCOXI C{SUB,1}-C{SUB,6}, ALQUILTIO C{SUB,1}-C{SUB,6}, ALQUILSULFINILO C{SUB,1}-C{SUB,6}, ALQUILSULFONILO C{SUB,1}-C{SUB,6} O TRIALQUILSILILO C{SUB,1}C{SUB,6}; AR{SUP,1} Y AR{SUP,2} SON CADA UNO ARILO OPCIONALMENTE SUSTITUIDO POR HALOGENO; A ES -CO- O -(CH{SUB,2})-; Z-A- ES ESTA EN LA POSICION 2 O 3 DEL ANILLO DE QUINUCLIDINA; Y Z ES HIDROXI, ALCOXI C{SUB,1}-C{SUB,6}, NR{SUP,1}R{SUP,2} O SIMILAR. EJEMPLOS TIPICOS SON (3S,4R,5S,6S)-5-(3,5-BIS(TRIFLUOMETIL)BENCILOXI)-N,NDIMETIL-6-DIFENILMETIL-1-AZABICICLO[2.2.2]OCTAN-3-CARBOXAMIDA; ACIDO (3S,4R,5S,6S)-5-(3,5-BIS(TRIFLUOMETIL)BENCILOXI)-6DIFENILMETIL-1-AZABICICLO[2.2.2]OCTAN-3-CARBOXILICO. LAS NUEVAS BENCILOXIQUINUCLIDINAS DE ESTA INVENCION POSEEN UNA ACTIVIDAD ANTAGONISTA A LA SUSTANCIA P Y POR TANTO SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ALERGIAS, ENFERMEDADES INFLAMATORIAS, ASMA, DOLORES, EMESIS, MIGRAÑA, INCONTINENCIA URINARIA O ANGIOGENESIS DE MAMIFEROS, ESPECIALMENTE DE SERES HUMANOS.
ES94919851T 1993-07-15 1994-07-05 Benciloxiquinuclidinas como antagonistas de la sustancia p. Expired - Lifetime ES2121213T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17560993 1993-07-15

Publications (1)

Publication Number Publication Date
ES2121213T3 true ES2121213T3 (es) 1998-11-16

Family

ID=15999090

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94919851T Expired - Lifetime ES2121213T3 (es) 1993-07-15 1994-07-05 Benciloxiquinuclidinas como antagonistas de la sustancia p.

Country Status (10)

Country Link
US (1) US5869499A (es)
EP (1) EP0708771B1 (es)
JP (1) JP2843921B2 (es)
AT (1) ATE171945T1 (es)
CA (1) CA2167198C (es)
DE (1) DE69413822T2 (es)
DK (1) DK0708771T3 (es)
ES (1) ES2121213T3 (es)
FI (1) FI960156A0 (es)
WO (1) WO1995002595A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
WO1998033379A1 (en) * 1997-02-04 1998-08-06 The General Hospital Corporation A novel method for treating epidermal or dermal conditions
AU736510B2 (en) * 1997-06-27 2001-07-26 Nippon Kayaku Kabushiki Kaisha Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
BRPI0513359A (pt) 2004-07-15 2008-05-06 Amr Technology Inc tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
NZ565111A (en) 2005-07-15 2011-10-28 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
KR20120023072A (ko) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 （Ｓ）-7-（〔1,2,4〕트리아졸〔1,5-ａ〕피리딘-6-일）-4-（3,4-디클로로페닐）-1,2,3,4-테트라하이드로이소퀴놀린의 결정형 및 이의 용도
US8375635B2 (en) * 2009-08-26 2013-02-19 Richard Hellinga Apparatus for opening and closing overhead sectional doors
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CA2833009A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5631281A (en) * 1989-06-29 1997-05-20 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl α-substituted Trp-Phe- and phenethylamine derivatives
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
JP2807577B2 (ja) * 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
DE69220258T2 (de) * 1991-02-11 1997-12-18 Merck Sharp & Dohme Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
DE69214333T2 (de) * 1991-03-22 1997-04-24 Merck & Co Inc Arzneizubereitung mit hohem Gehalt an Ibuprofenlysinat
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
DE69232334T2 (de) * 1991-05-22 2002-11-14 Pfizer Substituierte 3-aminochinuclidine
WO1993013083A1 (en) * 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
TW270927B (es) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5620989A (en) * 1992-10-28 1997-04-15 Merck Sharp & Dohme Limited 4-Arylmethyloxymethyl piperidines as tachykinin antagonsits
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
JPH06149350A (ja) * 1992-10-30 1994-05-27 Johnson Kk 自走車の誘導システム
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5622950A (en) * 1993-03-01 1997-04-22 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
US5607946A (en) * 1993-03-05 1997-03-04 Merck Sharp & Dohme Ltd. Quinolone derivatives as dopamine D4 ligands
US5622980A (en) * 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
GB9409882D0 (en) * 1994-05-18 1994-07-06 Sandoz Ltd Organic compounds
US5621004A (en) * 1994-06-03 1997-04-15 Robert W. Dunn Method for treating emesis
GB9413090D0 (en) * 1994-06-29 1994-08-17 Merck Sharp Benzazepine derivatives compositions containing them and their use in therapy
US5621140A (en) * 1994-12-22 1997-04-15 Syntex (U.S.A.) Inc. Resolution of ibuprofen
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation

Also Published As

Publication number Publication date
JP2843921B2 (ja) 1999-01-06
FI960156A (fi) 1996-01-12
WO1995002595A1 (en) 1995-01-26
EP0708771A1 (en) 1996-05-01
EP0708771B1 (en) 1998-10-07
JPH08511028A (ja) 1996-11-19
DE69413822T2 (de) 1999-02-25
DK0708771T3 (da) 1999-06-21
ATE171945T1 (de) 1998-10-15
US5869499A (en) 1999-02-09
FI960156A0 (fi) 1996-01-12
CA2167198C (en) 1999-03-16
CA2167198A1 (en) 1995-01-26
DE69413822D1 (de) 1998-11-12

Similar Documents

Publication Publication Date Title
ES2121213T3 (es) Benciloxiquinuclidinas como antagonistas de la sustancia p.
BR0212468A (pt) Compoto de uréia ativos como antagonistas de receptor de vanilóides para o tratamento de dor
DE60127595T2 (de) Inhibitoren der TNF-Alpha Bildung zur Behandlung von Autoimmunerkrankungen
DE69333143D1 (de) Substituierte chinuclidine als substanz p antagonisten
FI935134A0 (fi) Substituerade 3-aminokinuklidiner
SE9902987D0 (sv) Novel compounds
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
BR0214825A (pt) Uréias de 2-aminobenzotiazóis como moduladores de adenosina
ATE236158T1 (de) Bicyclische und tricyclische heteroaromatische verbindungen
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
EE03262B1 (et) Imidaso[1,2-a]püridiinidest saadavad alkoksüalküülkarbamaadid, nende valmistamine ja kasutamine
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
ATE301642T1 (de) Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
ATE370147T1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
BR0116724A (pt) Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 708771

Country of ref document: ES